How Polycystic Ovary Syndrome Disrupts Hormones and Fertility

PCOS Affects 1 in 10 Women — and Takes an Average of Two Years to Diagnose

Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, affecting an estimated 8–13% of this population globally according to the World Health Organization. Despite its prevalence, diagnosis is frequently delayed by an average of two years — often because symptoms like irregular periods and acne are dismissed as normal variation. PCOS is responsible for approximately 70–80% of anovulatory infertility, making it the leading cause of female infertility in high-income countries. It is also a significant metabolic disorder: women with PCOS have four to seven times the lifetime risk of developing type 2 diabetes compared to age-matched controls.

The Hormonal Cascade: What Actually Goes Wrong

PCOS does not originate in the ovaries. The name is misleading — the polycystic appearance (multiple small follicles arrested in development, visible on ultrasound) is a consequence, not the cause. The disorder begins with two intersecting dysfunctions: insulin resistance and hypothalamic-pituitary dysregulation.

In 60–80% of women with PCOS, cells resist the action of insulin, forcing the pancreas to produce more. Elevated insulin stimulates theca cells in the ovaries to produce excess androgens (primarily testosterone and androstenedione). High androgens disrupt normal follicle development, preventing any single follicle from maturing and releasing an egg — a process called anovulation. The pituitary gland also secretes abnormally elevated LH (luteinizing hormone) relative to FSH (follicle-stimulating hormone), further driving androgen production while failing to trigger ovulation.

The Three Diagnostic Features (Rotterdam Criteria)

• Oligo- or anovulation: Irregular or absent menstrual cycles (fewer than nine periods per year is a common threshold).
• Clinical or biochemical hyperandrogenism: Excess androgen demonstrated by hirsutism (unwanted hair growth on the face, chest, abdomen), acne, female-pattern hair loss, or elevated serum testosterone/free androgen index.
• Polycystic ovarian morphology on ultrasound: 20 or more follicles per ovary, or ovarian volume exceeding 10 mL on transvaginal ultrasound.

Diagnosis requires two of these three features, after exclusion of other causes of hyperandrogenism (congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors).

Clinical Features Across Body Systems

Fertility and Ovulation Induction

For women trying to conceive, ovulation induction is the primary goal. Multiple approaches are available, with selection based on body weight, metabolic profile, and prior treatment history.

• Letrozole (aromatase inhibitor): Now the first-line pharmacological agent for ovulation induction in PCOS, per the 2023 update from major fertility societies. Letrozole produces higher live birth rates than clomiphene citrate in overweight women with PCOS.
• Clomiphene citrate: Long the standard first-line agent, it remains widely used. It works by blocking estrogen receptors in the hypothalamus, increasing GnRH pulsatility and FSH secretion to stimulate follicle development.
• Metformin: An insulin sensitizer that reduces hyperinsulinemia. Improves menstrual regularity and ovulation rates, particularly in insulin-resistant women. Often used adjunctively with letrozole or clomiphene.
• Gonadotropins: Injected FSH for patients who don't respond to oral agents; requires close ultrasound monitoring due to risk of ovarian hyperstimulation syndrome (OHSS).
• Laparoscopic ovarian drilling: Surgical puncturing of follicles reduces androgen-producing tissue; comparable efficacy to gonadotropins, with lower OHSS risk.

Management Beyond Fertility

Lifestyle as Medicine

The evidence for lifestyle intervention in PCOS is compelling. A 5–10% reduction in body weight in overweight women with PCOS restores ovulation in the majority, reduces androgen levels, improves insulin sensitivity, and lowers long-term cardiometabolic risk — without any pharmacological agent. Resistance training has a particularly strong effect on insulin sensitivity. Low-glycemic-index diets reduce postprandial insulin spikes and have shown superiority over low-fat diets in improving menstrual regularity in small trials.

PCOS is a lifelong condition. Symptoms change across the lifespan — fertility concerns dominate reproductive years, while metabolic risk becomes the primary concern after menopause. Continuous monitoring of blood glucose, lipids, and blood pressure is part of long-term management.

This article is for informational purposes only. Consult a qualified healthcare professional for diagnosis and treatment of PCOS or any endocrine or reproductive health condition.